Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Deals

Eli Lilly Close to Acquiring Verve Therapeutics for Up to USD 1.3 Billion

Fineline Cube Jun 17, 2025

US-based pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) is reportedly in advanced negotiations to...

Company Drug

Pediatrix Therapeutics Wins Macau Approval for Neffy Epinephrine Nasal Spray

Fineline Cube Jun 17, 2025

China-based Pediatrix Therapeutics announced that it has received marketing approval in Macau for its neffy...

Company Drug

Minova Pharmaceuticals Launches Rongzhi, China’s First Injectable Adipocytolytic Drug

Fineline Cube Jun 17, 2025

Nanjing-based Minova Pharmaceuticals Co., Ltd announced last week that it has received marketing approval from...

Legal / IP

RemeGen Secures 1,827-Day Patent Extension for Telitacicept in China

Fineline Cube Jun 17, 2025

China-based pharmaceutical firm RemeGen (HKG: 9995) announced that the China National Intellectual Property Administration has...

Company Drug

Fujian Cosunter Gains Ethics Approval for Phase III Study of Neracorvir in CHB Patients

Fineline Cube Jun 17, 2025

China-based Fujian Cosunter Pharmaceutical Co., Ltd. (SHE: 300436) announced that it has received ethical approval...

Company Drug

CDE Accepts NDA for Ark Bio’s Azstarys, a Priority-Reviewed ADHD Treatment

Fineline Cube Jun 17, 2025

China’s Center for Drug Evaluation (CDE) has officially accepted the New Drug Application (NDA) for...

Company Drug

Ascentage Pharma Highlights Hematology Advances at EHA 2025, Focus on Olverembatinib and APG-5918

Fineline Cube Jun 17, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) unveiled 13 research presentations at the 2025 European...

Company Deals

Clover Biopharmaceuticals Terminates Adimmune Influenza Vaccine Pact Over Market Shifts

Fineline Cube Jun 17, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced the exercise of unilateral termination rights under its...

Company Drug

Fosun Pharma’s Serplulimab Approved in Singapore and Malaysia for ES-SCLC Treatment

Fineline Cube Jun 17, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai...

Policy / Regulatory

China’s NHC Unveils 2025 Healthcare Reforms to Tackle Procurement and Service Irregularities

Fineline Cube Jun 16, 2025

China’s National Health Commission (NHC) has released the 2025 Key Tasks for Rectifying Improper Practices...

Company Deals Medical Device

Thermo Fisher Mulls $4B Diagnostic Business Sale Amid Healthcare Sector Turbulence

Fineline Cube Jun 16, 2025

US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) is reported by the Financial...

Company Drug

Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial

Fineline Cube Jun 16, 2025

China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary...

Company Drug

Novo Nordisk Advances Amycretin for Weight Management in Phase III Trials

Fineline Cube Jun 16, 2025

Denmark-based pharmaceutical major Novo Nordisk (NYSE: NVO) announced plans to advance both subcutaneous and oral...

Company Drug

FDA OKs MSD’s Keytruda for Perioperative Head and Neck Cancer Treatment With PD-L1 Expression

Fineline Cube Jun 16, 2025

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that the US Food...

Company Drug

GSK Seeks EMA Approval to Expand RSV Vaccine Arexvy Use to Adults Aged 18+

Fineline Cube Jun 16, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has announced that the European Medicines Agency (EMA)...

Company

UCB Announces Investment in U.S. Biologics Production Facility

Fineline Cube Jun 16, 2025

Belgium-based biopharmaceutical company UCB (EBR: UCB) announced plans to invest in a cutting-edge biologics production...

Company Deals

Gene Solutions Partners with Shenzhen USK Bio to Advance Precision Oncology in Southern China

Fineline Cube Jun 16, 2025

Vietnam-headquartered Gene Solutions announced a Memorandum of Understanding (MOU) with China’s Shenzhen USK Bioscience Co.,...

Company Deals

MRI and Astellas Alliance to Boost Japanese Drug Discovery Startups

Fineline Cube Jun 16, 2025

Japan-based Mitsubishi Research Institute, Inc. (MRI) and Astellas Pharma Inc. (TYO: 4503) announced the signing...

Company Drug

MSD Wins NMPA Approval for Keytruda-Lenvima Combo in Hepatocellular Carcinoma

Fineline Cube Jun 16, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration...

Company Deals

Xuanzhu Biopharma Files for Hong Kong IPO to Advance Innovative Drug Pipeline

Fineline Cube Jun 16, 2025

Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460),...

Posts pagination

1 … 138 139 140 … 661

Recent updates

  • Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer
  • Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations
  • BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year
  • Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio
  • Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Others

Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations

Company

BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year

Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.